Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer
Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Matthew H. Kulke(Moffitt Cancer Center), Charles S. Fuchs(University of Southern California), Michele Houghton(Taiho Oncology (United States)), David P. Ryan(East Carolina University), Hiroshi Anbe(Taiho Oncology (United States)), Jeffrey W. Clark(Massachusetts General Hospital), Peter C. Enzinger(Dana-Farber Cancer Institute), Joshua Zhang(Taiho Oncology (United States)), P. D. Urrea(Taiho Oncology (United States)), Craig C. Earle(Canadian Partnership Against Cancer), Eileen Regan(Dana-Farber Cancer Institute), Jeffrey A. Meyerhardt(CancerCare)
Cited by 32
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k